ESR1 and neoplasm: However, the BRCA1-2 mutation rates were significantly higher in the subsets of patients with a more undifferentiated primary carcinoma (tumor grading 3–4, P < 0.001) and lack of expression of estrogen receptor (ER-, P = 0.002) or progesterone receptor (PR-, P = 0.007).